Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A liver biopsy required within 3 years prior to screening unless the patient has a contraindication for a liver biopsy~* Patients with bridging fibrosis or cirrhosis and without a liver biopsy result within 2 years prior screening must have an ultrasound taken within 2 months prior to the screening visit or during screening with no findings suspicious for hepatocellular carcinoma (HCC)~* Genotype-1 hepatitis C virus (HCV) infection~* Plasma HCV ribonucleic acid (RNA) of more than 10,000 IU per mL~* Documented human immunodeficiency virus-type 1 (HIV-1) infection at least 6 months prior to screening~Exclusion Criteria:~* Patient showing evidence of hepatic decompensation (ie, history or current evidence of ascites, bleeding varices or hepatic encephalopathy, albumin serum concentration less than 3.3 gm per dL, prolonged prothrombin time \[PT\] expressed as international normalized ratio \[INR\] more than 1.5)~* Any liver disease of non-HCV etiology~* Co-infection with hepatitis B virus (hepatitis B surface antigen \[HBsAg\] positive)~* An acute HIV-1 infection; or HIV-2 infection~* Change in antiretroviral (ARV) regimen within the last 4 weeks prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- TMC435 + pegylated interferon alpha-2a + ribavirin (Type: EXPERIMENTAL): Patients will be administered TMC435 150 mg along with pegylated interferon alpha-2a 180 microgram and ribavirin 1000 or 1200 mg for 12 weeks. Pegylated interferon alpha-2a and ribavirin will only be continued until 24 to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).